Market Newsdesk

ROCHESTER, N.Y., March 03, 2022 (GLOBE NEWSWIRE) — Impact Biomedical, Inc., a wholly owned subsidiary of DSS, Inc. (NYSE American: DSS), along with its scientific research partner Global Research and Discovery Group Sciences, (GRDG) announced it had received a positive report regarding the potential international patentability of its proprietary compound Equivir to treat viral infections which has shown potential to limit the occurrence of, and reduce, the risk or severity of viral outbreaks.

What is a Global Patent Application?

Patents awarded on a country basis, and, as such, are only enforceable within that country only, leaving the door open for the possibility of someone in another country to apply for a patent in their region, limiting the reach of the initial patent-holder. Global patent applications can be filed with the World Intellectual Property Organization (WIPO), an agency operating under the United Nations and is responsible for administering several international treaties relating to patents and other intellectual property rights. There are a total of 184 members of WIPO, including the U.S., China, and many European countries.

WIPO allows inventors to file one patent application, indicating on the application in which member states he or she wishes to obtain protection. This eliminates the need to file several patent applications simultaneously with different member states. In addition, WIPO, though a divisional referred to as the International Searching Authority (“ISA”), performs a search for potential prior art and a preliminary examination of the claims. The ISA issues its finding in a Patentability Report.

The Patentability Report received from the ISA regarding International application No. PCT/US2021/22538, directed the use of a composition containing Myricetin and G-hesperidin to treat viral infections determined that no prior art was found which would preclude the possibility of obtaining patent protection and that all claims were patentable.

“The receipt of this clean patentability report for Equivir’s international patent application is demonstrative of our desire to make Impact Biomedical’s antiviral innovations available to protect people worldwide,” said Frank. D. Heuszel, CEO of DSS.

This is the third step

This is the third positive step for Equivir, which is believed can limit the spread and severity of several viruses that lower the quality of life for people in the U.S. and abroad.

The first step occurred when Impact BioMedical received its first Equivir patent (US 10,383,842), which focused on influenza, from the U.S. Patent and Trademark Office on August 20, 2019.

Less than two years later, on June 15, 2021, the USPTO granted a second patent, this time focused on both Ebola and the rhinovirus.

How does Equivir work?

Equivir is believed to block the entry of virus to host cells and thereby prevent infection and replication in host cells. Taken much like a multivitamin, Equivir is a novel blend of FDA Generally Recognized as Safe (GRAS) eligible polyphenols.

In addition to its effects against various serotypes of influenza, Equivir is also believed to block the entry of Ebola virus into host cells which can prevent Ebola Virus Disease (EVD) and Ebola Hemorrhagic fever (EHF). These diseases are rare, but severe and often fatal in humans, particularly in sub-Saharan Africa. Ebola has a 90-percent death rate, according to the World Health Organization. Rhinovirus is the most common viral infectious agent in humans and is the predominant cause of the common cold.

Equivir has also possible use in addressing the side-effects and duration of viral infections and SARS COV2.

“Over the past two years, we have all experienced the impact of a virus,” said Daryl Thompson, Impact BioLife’s Director of Scientific Initiatives and founder of the advanced research company GRDG Sciences, LLC. “It is hoped that Equivir can be used as a deployable strategic defense for a broad spectrum of viral infections.”

“It is Equivir’s potential against a wide variety of infectious diseases, coupled with a relatively straightforward manufacturing process which makes Equivir of potential value around the world,” according to GRDG’s Chief Scientific Advisor Dr. Roscoe M. Moore, Jr., United States Assistant Surgeon General (Retired) and former Epidemic Intelligence Service (EIS) Officer at U.S. Center for Disease Control and Prevention. “While the threat of viral infections remains significant, it is Equivir’s ability to be quickly deployed as a working solution wherein such a treatment can be significant.”

About Impact BioMedical, Inc.

Impact BioMedical, Inc. (“Impact BioMedical”) is a wholly owned subsidiary of DSS. Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDG Sciences, LLC, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno related diseases. For more information on Impact BioMedical visit http://impbio.com/.

About DSS, Inc.

DSS is a multinational company operating business segments in blockchain security, direct marketing, healthcare, consumer packaging, real estate, renewable energy, securitized digital assets, securities trading and fund management, and banking, lending, and finance. Its business model is based on a distribution sharing system in which shareholders receive shares in its subsidiaries as DSS strategically unlocks value through IPO spinoffs. Under new leadership since 2019, DSS has built the necessary foundation for sustainable growth through the acquisition and formation of a diversified portfolio of companies positioned to drive profitability in five high-growth sectors. These companies offer innovative, flexible, and real-world solutions that not only meet customer needs, but create sustainable value and opportunity for transformation.

For more information on DSS visit http://www.dssworld.com

Investor Contact:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
[email protected]

Safe Harbor Disclosure

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements related to the Company’s intended use of proceeds and other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of development activities; our ability to attract, integrate and retain key personnel; our need for substantial additional funds; patent and intellectual property matters; competition; as well as other risks described in our SEC filings, including, without limitation, our reports on Forms 8-K, 10-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations, and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

CERRITOS, Calif., March 03, 2022 (GLOBE NEWSWIRE) — The Oncology Institute of Hope and Innovation (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, announced a value-based agreement with MaxHealth to provide medical oncology care to patients in Pinellas and Hillsborough Counties. Starting in the Tampa Bay Area, TOI and MaxHealth intend to expand the footprint of the agreement into neighboring counties in coming months.

“We are extremely excited to launch this important partnership with a high-quality primary care organization like MaxHealth,” shared Dr. Daniel Virnich, Chief Operating Officer at TOI. “MaxHealth has a reputation for providing outstanding care coordination and services for patients in the counties that they serve, and we believe that our oncology model is ideally suited to extend exceptional care to their patients that require oncology services.”

TOI uses an outcomes and quality-based incentive model to improve patient satisfaction and clinical results. By bringing cutting-edge cancer care into the community setting, including full-service medical oncology care, 170+ clinical trials, blood product transfusions, stem cell transplants, and dispensary services, TOI is reimagining how specialty care can be delivered.

“We are thrilled to partner with TOI to provide best-in-class cancer care for our patients,” added Kim Ficocelli, Co-founder and Chief Growth Officer for MaxHealth. “TOI shares our commitment to personalized care and patient satisfaction – we know our patients will be in good hands.”

TOI began serving MaxHealth patient in Pinellas and Hillsborough counties on March 1.

About The Oncology Institute

Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.6 million patients including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced healthcare organizations. With 80+ employed clinicians and more than 600 teammates in more than 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.

About MaxHealth

The MaxHealth Network is a network of primary care facilities for adults and seniors with over 50 locations throughout Florida. MaxHealth is reinventing the healthcare experience. With a focus on value-based care and provider-patient relationships, our patients experience advanced medical care, delivered by highly-trained, board-certified physicians who treat their patients like family. From caregivers to staff, MaxHealth is devoted to the patient experience. It’s personal to us… it matters. From a friendly greeting at the front desk to a doctor taking extra time to really listen to the patient, this approach can be felt throughout the company.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations. These statements are based on various assumptions and on the current expectations of The Oncology Institute and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of The Oncology Institute. These forward-looking statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which The Oncology Institute may become a party or governmental investigations to which The Oncology Institute may become subject that could interrupt or limit The Oncology Institute’s operations, result in adverse judgments, settlements or fines and create negative publicity; changes in The Oncology Institute’s clients’ preferences, prospects and the competitive conditions prevailing in the healthcare sector; failure to continue to meet stock exchange listing standards; the impact of COVID-19 on The Oncology Institute’s business; those factors discussed in the documents of The Oncology Institute filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that The Oncology Institute presently know or currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect The Oncology Institute’s expectations, plans or forecasts of future events and views as of the date of this press release. The Oncology Institute anticipate that subsequent events and developments will cause The Oncology Institute’s assessments to change. The Oncology Institute do not undertake any obligation to update any of these forward-looking statements. These forward-looking statements should not be relied upon as representing The Oncology Institute’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts

Media

The Oncology Institute
Julie Korinke
[email protected]
(562) 735-3226 x 88806

Revive
Michael Petrone
[email protected]
(615) 760-4542

Investors

Solebury Trout
Maria Lycouris
[email protected]

BRIDGEWATER, N.J., March 03, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, Chief Executive Officer, will participate in a virtual fireside chat at the 42nd Annual Cowen Healthcare Conference on March 8, 2022. Management will also be available for 1-on-1 meetings with investors.

Virtual Presentation Details

Date:		Tuesday, March 8th
Time:		12:50 p.m. ET
Format:		Virtual Fireside Chat
Webcast Link:		https://wsw.com/webcast/cowen108/vyne/2045898

The replay of the webcast will be available on the VYNE website for 90 days following the conference.

About VYNE Therapeutics Inc.

VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary pipeline includes FMX114 for the potential treatment of mild-to-moderate atopic dermatitis and access to a library of bromodomain & extra-terminal (BET) domain inhibitors that the Company is developing for the potential treatment of immuno-inflammatory conditions.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:

John Fraunces
LifeSci Advisors, LLC
917-355-2395
[email protected]

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
[email protected]

SECAUCUS, N.J., March 03, 2022 (GLOBE NEWSWIRE) — The Children’s Place, Inc. (Nasdaq: PLCE) today announced that, in conjunction with the release of its fourth quarter and full year 2021 financial results, you are invited to listen to the Company’s conference call on Wednesday, March 9, 2022, beginning at 8:00 a.m. Eastern Time.

To access the webcast, visit http://investor.childrensplace.com. An archive of the webcast can be accessed two hours after the live call has concluded.

About The Children’s Place

The Children’s Place is the largest pure-play children’s specialty apparel retailer in North America. The Company designs, contracts to manufacture, sells at retail and wholesale, and licenses to sell fashionable, high-quality merchandise predominantly at value prices, primarily under the proprietary “The Children’s Place”, “Place”, “Baby Place”, “Gymboree” and “Sugar & Jade” brand names. The Company has online stores at www.childrensplace.com, www.gymboree.com and www.sugarandjade.com and, as of October 30, 2021, the Company had 703 stores in the United States, Canada, and Puerto Rico and the Company’s eight international franchise partners had 221 international points of distribution in 17 countries. 

Forward Looking Statements

This press release contains or may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to the Company’s strategic initiatives and adjusted net income per diluted share. Forward-looking statements typically are identified by use of terms such as “may,” “will,” “should,” “plan,” “project,” “expect,” “anticipate,” “estimate” and similar words, although some forward-looking statements are expressed differently. These forward-looking statements are based upon the Company’s current expectations and assumptions and are subject to various risks and uncertainties that could cause actual results and performance to differ materially. Some of these risks and uncertainties are described in the Company’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of its annual report on Form 10-K for the fiscal year ended January 30, 2021. Included among the risks and uncertainties that could cause actual results and performance to differ materially are the risk that the Company will be unsuccessful in gauging fashion trends and changing consumer preferences, the risks resulting from the highly competitive nature of the Company’s business and its dependence on consumer spending patterns, which may be affected by changes in economic conditions, the risks related to the COVID-19 pandemic, including the impact of the COVID-19 pandemic on our business or the economy in general (including decreased customer traffic, schools adopting remote and hybrid learning models, closures of businesses and other activities causing decreased demand for our products and negative impacts on our customers’ spending patterns due to decreased income or actual or perceived wealth, and the impact of the CARES Act and other legislation related to the COVID-19 pandemic, and any changes to the CARES Act or such other legislation), the risk that the Company’s strategic initiatives to increase sales and margin are delayed or do not result in anticipated improvements, the risk of delays, interruptions and disruptions in the Company’s global supply chain, including resulting from COVID-19 or other disease outbreaks, or foreign sources of supply in less developed countries, more politically unstable countries, or countries where vendors fail to comply with industry standards or ethical business practices, including the use of forced, indentured or child labor, the risk that the cost of raw materials or energy prices will increase beyond current expectations or that the Company is unable to offset cost increases through value engineering or price increases, various types of litigation, including class action litigations brought under consumer protection, employment, and privacy and information security laws and regulations, the imposition of regulations affecting the importation of foreign-produced merchandise, including duties and tariffs, and the uncertainty of weather patterns. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they were made. The Company undertakes no obligation to release publicly any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact:  Investor Relations (201) 558-2400 ext. 14500 

FUZHOU, China, March 03, 2022 (GLOBE NEWSWIRE) — E-Home Household Service Holdings Limited (Nasdaq: EJH) (the “Company” or “E-Home”), a provider of integrated household services in China, today announced that the Company will debut a Digital Human as a Service (“DHaaS”) that will debut on March 18, 2022 leveraging frontend AI technologies following E-Home’s launch of metaverse initiatives.

DHaaS features a virtual digital human customer service guide named “Xiao Yi” who provides seamless, 24/7 assistance for household services clients in the Metaverse virtual world, all delivered with leading AI technologies that are developed via the Company’s in-house research as well as through partnership with various partners. For example, clients can experience easy navigation and interaction with the digital human customer service and obtain information on E-Home’s diversified household services, raise any inquiries they may have. The entire client experience is also augmented with virtual guidance signs and opens business-to-customer (B2C) options via advertiements and helpful information that can be placed precisely in the metaverse space. A video demonstrating the DHaaS is available at: http://www.ej111.com/business.html#technology.

Mr. Wenshan Xie, Chairman and CEO of E-Home, commented: “We are very proud to announce another major progress for our Metaverse strategy, which is launched to improve E-Home’s operation efficiency and lowers operational costs as standard training and customer services are digitalized in the virtual world and both our staff and customers can access these resources anytime, anywhere on demand. The consumer facing innovation is instrumental in developing and delivering the right technical capabilities to develop and optimize our business operation and diversified household services for our core clients.”

About E-Home Household Service Holdings Limited

E-Home Household Service Holdings Limited is a household service company based in Fuzhou, China. The Company, through its website and WeChat platform “e家快服”, provides integrated household services, including appliance installation and maintenance, housekeeping services, and Internet based home and senior care. For more information, visit the Company’s website at http://www.ej111.com/ir.html.

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements in nature within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions are intended to identify such forward-looking statements. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to consider risk factors, including those described in the Company’s filings with the SEC, that may affect the Company’s future results. All forward-looking statements attributable to the Company and its subsidiaries or persons acting on their behalf are expressly qualified in their entirety by these risk factors.

For more information, please contact:

Chunming Xie

Investor Relations

Email: [email protected]

Phone: +86 15359908086

Janice Wang

EverGreen Consulting Inc.

Email: [email protected]

Phone: +1 571-464-9470 (from U.S.)

           +86 13811768559 (from China)

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) — Apollo Commercial Real Estate Finance, Inc. (the “Company” or “ARI”) (NYSE:ARI) today announced the Company will participate in the Citi Global Property CEO Conference. Stuart Rothstein, the Company’s Chief Executive Officer, is scheduled to present on March 8, 2022 at The Diplomat Beach Resort in Hollywood, Florida. The presentation is scheduled to begin at 10:30 am ET.

Both presentations and question and answer periods will be broadcast live over the Internet and can be accessed by all interested parties through the Company’s website at www.apolloreit.com in the Stockholders section. There will be a replay available following the presentation which will remain on the Company’s website for thirty days.

About Apollo Commercial Real Estate Finance, Inc.

Apollo Commercial Real Estate Finance, Inc. (NYSE: ARI) is a real estate investment trust that primarily originates, acquires, invests in and manages performing commercial first mortgage loans, subordinate financings and other commercial real estate-related debt investments. The Company is externally managed and advised by ACREFI Management, LLC, a Delaware limited liability company and an indirect subsidiary of Apollo Global Management, Inc., a high-growth, global alternative asset manager with approximately $497 billion of assets under management at December 31, 2021.

Additional information can be found on the Company’s website at www.apolloreit.com.

Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking statements as such term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are intended to be covered by the safe harbor provided by the same. Forward-looking statements are subject to substantial risks and uncertainties, many of which are difficult to predict and are generally beyond the Company’s control. These forward-looking statements include information about possible or assumed future results of the Company’s business, financial condition, liquidity, results of operations, plans and objectives. When used in this release, the words believe, expect, anticipate, estimate, plan, continue, intend, should, may or similar expressions, are intended to identify forward-looking statements. Statements regarding the following subjects, among others, may be forward-looking: macro- and micro-economic impact of the COVID-19 pandemic; the severity and duration of the COVID-19 pandemic; actions taken by governmental authorities to contain the COVID-19 pandemic or treat its impact; the impact of the COVID-19 pandemic on the Company’s financial condition, results of operations, liquidity and capital resources; market trends in the Company’s industry, interest rates, real estate values, the debt securities markets or the general economy; the timing and amounts of expected future fundings of unfunded commitments; the return on equity; the yield on investments; the ability to borrow to finance assets; the Company’s ability to deploy the proceeds of its capital raises or acquire its target assets; and risks associated with investing in real estate assets, including changes in business conditions and the general economy. For a further list and description of such risks and uncertainties, see the reports filed by the Company with the Securities and Exchange Commission. The forward-looking statements, and other risks, uncertainties and factors are based on the Company’s beliefs, assumptions and expectations of its future performance, taking into account all information currently available to the Company. Forward-looking statements are not predictions of future events. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

CONTACT:	Hilary Ginsberg
	Investor Relations
	(212) 822-0767

SOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) — The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), today announced it is accepting proposals for the Access to Care Empowerment for Sickle Cell (ACE) Grant Program, which provides funding for community-based organizations (CBOs) to accelerate the development of sustainable access-to-care programs for people living with sickle cell disease (SCD). The 2022 ACE Grant Program will award five grants worth up to $50,000 each. The GBT Foundation will accept proposals from U.S.-based nonprofit CBOs dedicated to SCD to fund programs supporting SCD patient care, including patient empowerment, peer-to-peer education, healthcare navigation for patients and caregivers, and organizational capacity building.

The ACE Grant Program is a new extension of the ongoing Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program, which will now be led by The GBT Foundation and has provided funding since 2019 to U.S.-based nonprofit organizations and institutions that serve patients with SCD and their families and seeks to improve their access to high-quality healthcare. Based on feedback from the SCD community, The GBT Foundation is separating its funding for U.S.-based nonprofit organizations into two programs: the ACE Grant Program, to which U.S.-based CBOs are invited to apply now; and the fourth annual ACCEL Grant Program, which will begin accepting proposals in mid-2022 from nonprofit healthcare organizations and institutions.

“Community-based organizations are uniquely equipped to improve access to high-quality care for people with sickle cell disease, who have suffered for far too long from disparities in care and inequitable investment in their communities,” said Jung E. Choi, board member of The GBT Foundation and chief business and strategy officer and head of patient advocacy and government affairs at GBT. “We are immensely proud of the accomplishments of past grantees and eagerly await new proposals that align with The GBT Foundation’s mission to improve the health and well-being of underserved patient communities. We look forward to once again supporting these nonprofit partners in their essential work to create meaningful and sustainable change.”

Over its first three years, the ACCEL program funded nearly $1 million in total to 19 organizations to accelerate the development of sustainable and innovative programs for SCD patients. Previous recipients used grant funding for activities including augmenting provider education, helping organizations transition their patients from pediatric to adult care, creating community health worker initiatives, educating on the impact of COVID-19 on SCD, and expanding healthcare options for SCD patients in rural areas.

The GBT Foundation is accepting proposals for the ACE program through Friday, April 22, 2022, at 5:00 p.m. Pacific Time. A panel of representatives from The GBT Foundation and external stakeholders with expertise in the issues affecting people with SCD will review proposal submissions. The panel will select grant recipients based on the proposal’s goals and objectives consistent with the mission of The GBT Foundation, potential impact on SCD patient care, evaluation plan, organizational capabilities, and sustainability plan. More information about the ACE program and how to submit a proposal can be found here.

About Sickle Cell Disease

Sickle cell disease (SCD) affects more than 100,000 people in the United States,¹ an estimated 52,000 people in Europe,² and millions of people throughout the world, particularly among those whose ancestors are from sub-Saharan Africa.³ It also affects people of Hispanic, South Asian, Southern European and Middle Eastern ancestry.⁴ SCD is a lifelong inherited rare blood disorder that impacts hemoglobin, a protein carried by red blood cells that delivers oxygen to tissues and organs throughout the body.⁴ Due to a genetic mutation, individuals with SCD form abnormal hemoglobin known as sickle hemoglobin. Through a process called hemoglobin polymerization, red blood cells become sickled – deoxygenated, crescent-shaped and rigid.^4,5,6 The sickling process causes hemolytic anemia (low hemoglobin due to red blood cell destruction) and blockages in capillaries and small blood vessels, which impede the flow of blood and oxygen delivery throughout the body. The diminished oxygen delivery to tissues and organs can lead to life-threatening complications, including stroke and irreversible organ damage.^5,6,7,8 Complications of SCD begin in early childhood and can include neurocognitive impairment, acute chest syndrome, and silent and overt stroke, among other serious issues.⁹

About The GBT Foundation

Founded in 2021, The GBT Foundation is a 501(c)(3) nonprofit organization, primarily funded by Global Blood Therapeutics, Inc. (GBT). Building on GBT’s corporate giving commitment, The GBT Foundation is a community-focused, charitable entity that is committed to improving health equity worldwide, particularly for people living with SCD. The GBT Foundation is a separate legal entity from GBT. To learn more, please visit www.gbt.com/gbtfoundation.

About Global Blood Therapeutics

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program to address significant patient needs in SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

References

1. Centers for Disease Control and Prevention website. Sickle Cell Disease Research. https://www.cdc.gov/ncbddd/hemoglobinopathies/scdc-understanding-sickle-cell-disease.html. Accessed February 23, 2022.
2. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182125 Accessed February 23, 2022.
3. Centers for Disease Control and Prevention website. Sickle Cell Disease (SCD). https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed February 23, 2022.
4. National Heart, Lung, and Blood Institute website. Sickle Cell Disease. https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease. Accessed February 23, 2022.
5. Kato GJ, et al. Nat Rev Dis Primers. 2018;4:18010.
6. Rees DC, et al. Lancet. 2010;376(9757):2018-2031.
7. Kato GJ, et al. J Clin Invest. 2017;127(3):750-760.
8. Caboot JB, et al. Paediatr RespirRev. 2014;15(1):17-23.
9. Kanter J, et al. BloodRev. 2013 Nov;27(6):279-87.

Contact:
Steven Immergut (media)
+1 650-410-3258
[email protected]

ROCKAWAY, N.J., March 03, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the fourth quarter and year ended December 31, 2021, after the close of the market on Thursday, March 10, 2022. Management will host a conference call and webcast at 4:30 PM Eastern Standard Time to discuss the financial results and answer questions.

Thursday, March 10, 2022, 4:30 PM Eastern Standard Time


Domestic: 877-269-7756
International: 201-689-7817
Conference ID: 13726544
Webcast: electroCore Earnings Webcast

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com. 

Investors:

Rich Cockrell
CG Capital
404-736-3838
[email protected]
or
Media Contact:
Jackie Dorsky
electroCore
908-313-6331
[email protected]

OXFORD, Mass., March 03, 2022 (GLOBE NEWSWIRE) — IPG Photonics Corporation (NASDAQ: IPGP) today announced more information regarding its Russian operations in light of current events. IPG’s Russian facilities continue to operate and manufacture optical components and finished products for its operations in the U.S., Germany and China.

IPG has major production and R&D facilities as well as close to 2,000 employees located in Russia. These facilities supply components that Germany and the U.S. use in production and provides finished products to China and the U.S. In 2021, IPG’s Russian operations supplied approximately $100 million of finished product for the Chinese market. Historically, sales to Russian customers have been nominal, totaling $30 million in 2021.

Sanctions will increase lead times and shipping costs for components and lasers to and from IPG’s Russian operations. As part of contingency planning, IPG already has built several months of critical inventory in Russia to support sales. The Company’s Russian facility is currently able to ship optical and other components to IPG affiliates from Russia. In the event that sanctions or other developments resulting from the ongoing Russia-Ukraine war substantially limit IPG’s ability to export optical or other components to or from Russia, the Company’s sales may be materially impacted.

IPG is executing on contingency plans that include increasing manufacturing capacity and inventories of critical components in Germany and the U.S., and qualifying third-party suppliers to reduce reliance on Russian operations. Management believes that the Company can start to reduce the reliance on components sourced from Russia within a few months and substantially reduce the risk related to sourcing these components from Russia in six to nine months. Management continues to assess the impact of the announced sanctions and will monitor any new sanctions.

The current cash balance in Russia is less than 1% of total current cash and the Russian operations are self-funding. To preserve cash, IPG also suspended further capital investment in Russia other than for maintenance and non-material items. IPG has no operations in Ukraine.

On February 15, 2022, IPG provided earnings guidance for the first quarter of 2022. The estimates included in such guidance were current as of the date given and are not being updated or reaffirmed by this news release. Given the rapidly evolving situation, increased risk and uncertainty, IPG is withdrawing the annual guidance.

Contact

Eugene Fedotoff
Director of Investor Relations
IPG Photonics Corporation
508-597-4713
[email protected]

About IPG Photonics Corporation

IPG Photonics Corporation is the leader in high-power fiber lasers and amplifiers used primarily in materials processing and other diverse applications. The Company’s mission is to make its fiber laser technology the tool of choice in mass production. IPG accomplishes this mission by delivering superior performance, reliability and usability at a lower total cost of ownership compared with other types of lasers and non-laser tools, allowing end users to increase productivity and decrease costs. A member of the S&P 500® Index, IPG is headquartered in Oxford, Massachusetts and has more than 30 facilities worldwide. For more information, visit www.ipgphotonics.com.

Safe Harbor Statement        

Information and statements provided by IPG and its employees, including statements in this press release, that relate to future plans, events or performance are forward-looking statements. These statements involve risks and uncertainties. Any statements in this press release that are not statements of historical fact are forward-looking statements, including, increase in lead times and shipping costs for components and lasers to and from our Russian operations, increasing manufacturing capacity and inventories of critical components in Germany and the U.S. and qualifying third-party suppliers to reduce reliance on Russian operations, to reduce the reliance on components sourced from Russia within a few months and substantially reduce the risk related to sourcing these components from Russia in six to nine months. Factors that could cause actual results to differ materially include risks and uncertainties, including risks associated with the strength or weakness of the business conditions in industries and geographic markets that IPG serves, particularly the effect of downturns in the markets IPG serves; uncertainties and adverse changes in the general economic conditions of markets; IPG’s ability to penetrate new applications for fiber lasers and increase market share; the rate of acceptance and penetration of IPG’s products; inability to manage risks associated with international customers and operations; changes in trade controls and trade policies; foreign currency fluctuations; high levels of fixed costs from IPG’s vertical integration; the appropriateness of IPG’s manufacturing capacity for the level of demand; competitive factors, including declining average selling prices; the effect of acquisitions and investments; inventory write-downs; asset impairment charges; intellectual property infringement claims and litigation; interruption in supply of key components; manufacturing risks; government regulations and trade sanctions; and other risks identified in IPG’s SEC filings. Readers are encouraged to refer to the risk factors described in IPG’s Annual Report on Form 10-K (filed with the SEC on February 22, 2022 and IPG’s reports filed with the SEC, as applicable. Actual results, events and performance may differ materially. Readers are cautioned not to rely on the forward-looking statements, which speak only as of the date hereof. IPG undertakes no obligation to update the forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) — SpringServe, the leading independent TV ad serving platform, today announced the launch of BidLink. BidLink is designed to communicate with a publisher’s primary ad server to send dynamic programmatic demand insights from integrated video SSPs, enabling competition between traditional-direct and programmatic campaigns. Publishers can leverage BidLink’s capabilities regardless of which ad server they use.

“We developed BidLink to be the best mechanism for unifying ad decisioning across programmatic and traditional direct-sold deals,” said Joe Hirsch, GM of SpringServe. “BidLink provides publishers with an out-of-the-box, fully transparent integration with over 22 SSPs. This gives publishers the opportunity to uplevel their programmatic demand capabilities, whether or not they use SpringServe as their primary ad server.”

“We’re excited about the prospect of using SpringServe’s BidLink to help improve yield by holding a true real-time auction across all demand partners,” said Tom Sly, vice president, programmatic revenue, for The E.W. Scripps Company.

BidLink communicates with a publisher’s primary ad server to send dynamic programmatic demand insights from integrated video SSPs, including price, ad category and priority levels, to help better inform decisioning and provide publishers with the best revenue outcome. Publishers leveraging BidLink can better control logic and other advertising and business rules, such as competitive separation, to maximize yield and ensure campaign success across execution types. BidLink also provides publishers with live reporting which helps them react to the market in real-time and make faster decisions.

About SpringServe

SpringServe, now part of Magnite, is the leading independent TV ad serving platform, purpose-built for OTT, CTV and video advertising. Its software offers a full stack of ad serving, optimization and automation solutions that make video ad serving smarter across devices. Trusted by leading publishers & advanced TV distributors, its platform delivers control, transparency, and analytics to increase ad performance and revenue from media sales. For more information, visit http://www.springserve.com.

Media Contact

Kar Yi Lim
[email protected]
917-658-1994